# Viatris

> Viatris makes and markets generic, complex generic and branded medicines worldwide. Formed by combining Mylan and Pfizer’s Upjohn business in 2020, it pairs a broad supply network with established brands and investments in innovative medicines.

- **Founded:** 2020
- **Headquarters:** Canonsburg, United States
- **Products:** Generic and complex generic medicines, Established brands, RYZUMVI, Development and commercialization partnerships
- **Notable:** Established through the Mylan-Upjohn combination in November 2020., Sells medicines across more than 165 countries and territories., Wixela Inhub was the first generic of Advair Diskus.

## Products & services

- **Generic and complex generic medicines** — Portfolio includes Wixela Inhub and other oral, injectable, inhaled and transdermal medicines; availability varies by country.
- **Established brands** — Portfolio includes Lipitor, Norvasc, Lyrica, Viagra and other branded treatments; local rights and approvals vary.
- **RYZUMVI** — Phentolamine ophthalmic solution 0.75%; FDA approval expanded to presbyopia in adults in October 2026.
- **Development and commercialization partnerships** — Licenses and develops assets with external companies, including the Idorsia collaboration.

## Achievements

- Established through the Mylan-Upjohn combination in November 2020.
- Sells medicines across more than 165 countries and territories.
- Wixela Inhub was the first generic of Advair Diskus.
- Completed the previously announced major divestitures by July 2024.
- Reported second-quarter 2026 revenue of $3.8 billion, up 5% on a reported basis.

## Latest updates

- **2026-10** — October 16: announced FDA approval of RYZUMVI for presbyopia in adults and said it was exploring a U.S. commercialization partner.
- **2026-10** — October 8: agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion; expected closing by year-end, subject to conditions.
- **2026-08** — Reported Q2 revenue of $3.8 billion and a $119 million GAAP net loss; raised full-year guidance midpoints.
- **2026-02** — Announced restructuring expected to entail $700 million to $850 million in pre-tax charges and workforce reductions of up to approximately 10%.

## Links

- Website: https://www.viatris.com
- LinkedIn: https://www.linkedin.com/company/viatris
- Twitter/X: https://twitter.com/viatrisinc
- YouTube: https://www.youtube.com/viatris
- Instagram: https://www.instagram.com/viatrisinc/
- Facebook: https://www.facebook.com/ViatrisInc/

---

Profile page: https://yespress.io/viatris
Published by YesPress — https://yespress.io
Last updated: 2026-10-22